Key Takeaways TCO Has Permanently Replaced PPV as the Operating Metric. Purchase Price Variance (PPV) models are inadequate for pharmaceutical […]
The Cost Structure That Makes AI Non-Optional Bringing a New Molecular Entity (NME) to market costs, on average, US $2.8
1. Executive Strategic Overview The Indian pharmaceutical industry, historically celebrated as the “Pharmacy of the World” for its unparalleled capacity
1. The Opportunity in Numbers: Patent Cliff Sizing and Market Structure Global Market Scale and Growth Trajectory The global generic
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits Read Post »
For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook Read Post »
1. Why Generic Drug Market Entry Demands a Different Analytical Framework Generic pharmaceutical market entry is not a standard product
For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Get fresh news and insights, drug patent expirations & more…
